Normodin (Amlodipine)

Amlodipine, the active ingredient in Normodin, is a calcium channel blocker presented as an oral tablet for oral use. It is used to lower high blood pressure and to relieve chest pain caused by reduced blood flow to the heart in adult patients. GNH USA supplies Normodin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Amlodipine acts on the cardiovascular system to manage conditions related to elevated blood pressure and coronary artery disease. - Hypertension: lowers systolic and diastolic blood pressure, reducing the risk of stroke and heart attack. - Chronic stable angina: improves exercise tolerance by decreasing myocardial oxygen demand. - Coronary artery disease: helps prevent ischemic episodes by enhancing coronary blood flow.

Amlodipine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Flushing: transient warmth and redness. - Dizziness: especially upon standing. - Fatigue: general tiredness. - Nausea: occasional stomach upset.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: abnormal liver enzymes. - Allergic reactions: rash, itching, or swelling. - Atrioventricular block: conduction disturbances.

Before initiating therapy, consider patient‑specific factors and monitor appropriately. - Renal impairment: adjust monitoring as clearance may be reduced. - Hepatic disease: use with caution; monitor liver function. - Concomitant antihypertensives: risk of additive blood pressure lowering. - Pregnancy: safety not established; avoid unless clearly needed. - Lactation: unknown excretion in breast milk; assess risk‑benefit. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Amlodipine can interact with several drug classes, requiring vigilance.

Major Interactions (Avoid): - Simultaneous use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase amlodipine levels and cause hypotension. - Co‑administration with other calcium channel blockers: additive cardiovascular effects.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, phenytoin): may reduce efficacy. - Beta‑blockers: may enhance bradycardia. - Digoxin: increased serum concentrations reported. - Statins metabolized by CYP3A4 (e.g., simvastatin): higher risk of myopathy.